5 recruiting, 3 completed, 2 active not recruiting, 1 not yet recruiting. 13 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 5, Completed 3, Active not recruiting 2, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Lung Carcinoma: new trials by email Literature Review of Lung Carcinoma trials Research Report on Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the SurVaxM Vaccine for Lung Cancer Prevention Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration - Lung Carcinoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 80 | 2026-10-01 | 2026-08-26 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| A Study of SKB518 in Patients With Lung Cancer SKB518, Tislelizumab, Carboplatin - Lung Carcinoma | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 192 | 2025-08-29 | 2026-05-08 |
| Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer Biospecimen Collection, Oligo-fucoidan, Placebo Administration - Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm | Phase 2 | Recruiting | Mayo Clinic | 34 | 2025-03-06 | 2026-10-16 |
| Oral Iloprost for the Prevention of Lung Cancer In Former Smokers Biospecimen Collection, Bronchial Brush Biopsy, Bronchoscopy - Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-06-01 | 2024-05-17 | |
| Evaluation of Canakinumab in High-Risk Former-Smokers Biospecimen Collection, Bronchoscopy, Canakinumab - Cigarette Smoking-Related Carcinoma, Lung Carcinoma | Phase 2 | Completed | Peter Shields | 41 | 2024-03-11 | 2026-07-07 |
| Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer Biopsy, Biospecimen Collection, Bronchoscopy - Lung Carcinoma | Phase 2 | Active not recruiting | Northwestern University | 50 | 2022-09-09 | 2026-11-13 |
| Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial Canakinumab, Quality-of-Life Assessment - Lung Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2021-07-20 | 2026-06-12 |
| Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma Apatinib - Lung Carcinoma | Phase 2 | Unknown | Guangzhou Institute of Respiratory Disease | 33 | 2018-10-19 | 2018-10-24 |
| Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery Near-Infrared Fluorescence Imaging, Panitumumab-IRDye800, Pharmacokinetic Study - Lung Carcinoma, Metastatic Malignant Neoplasm in the Lung | Phase 1 / Phase 2 | Recruiting | Stanford University | 30 | 2018-07-19 | 2026-10-05 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-11-12 |
| 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules Computed Tomography, fluorodeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392 - Lung Carcinoma, Solitary Pulmonary Nodule | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 46 | 2015-06-16 | 2022-10-19 |
| Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers Aspirin, Laboratory Biomarker Analysis, Placebo - Lung Carcinoma, Tobacco Use Disorder | Phase 2 | Completed | National Cancer Institute (NCI) | 54 | 2014-06-01 | 2018-08-29 |
Lung Neoplasms (13) · Breast Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Melanoma (2) · Multiple Myeloma (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Urinary Bladder Neoplasms (2) · Uterine Cervical Neoplasms (2) · Amyloidosis (1) · Carcinoma, Basal Cell (1)
Lung Diseases (13) · Neoplasms (13) · Neoplasms by Site (13) · Respiratory Tract Diseases (13) · Respiratory Tract Neoplasms (13) · Thoracic Neoplasms (13) · Breast Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Adenocarcinoma (2) · Adnexal Diseases (2) · Blood Protein Disorders (2)
Specimen Handling (6) · Bronchoscopy (3) · Biopsy (2) · Magnetic Resonance Spectroscopy (2) · canakinumab (2) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · 4-(3-fluoropropyl)glutamic acid (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Antineoplastic Protocols (1) · Aspirin (1) · CT-P6 (1) · Carbon Monoxide (1)
National Cancer Institute (NCI) (4) · Mayo Clinic (2) · Guangzhou Institute of Respiratory Disease (1) · M.D. Anderson Cancer Center (1) · Northwestern University (1) · Peter Shields (1) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (1) · Stanford University (1) · Vanderbilt-Ingram Cancer Center (1)
United States (10) · China (2) · Canada (1) · Guam (1) · Puerto Rico (1)
Saikrishna S Yendamuri (2) · Chirayu Shah, MD (1) · Jianjun Zhang (1) · Keith T Flaherty (1) · Linda Garland (1) · Natalie Lui (1) · Peter G Shields, MD (1) · Roxana S. Dronca, MD (1) · York E Miller (1) · Zoey I. Harris, MD (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729
P30CA060553 (3), UG1CA242643 (3), N01CN00031 (1), P30CA023074 (1), P30CA068485 (1), U10CA180820 (1), U24CA196172 (1)